Cantor Fitzgerald Raises GW Pharma's Target To $235 Following Epidiolex Approval

The U.S. Food and Drug Administration on Monday announced the approval of GW Pharmaceuticals PLC- ADR GWPH’s cannabidiol-based Epidiolex for the treatment of two rare childhood-onset forms of epilepsy that are commonly treatment-resistant.

“The acknowledgement by the FDA of cannabis’ potential medical efficacy is likely to rekindle debates as to the proper classification of cannabis, and particularly cannabidiol (CBD), the main active ingredient in GW’s product, under the Controlled Substances Act,” Harrison Phillips, vice president at Viridian Capital Advisors, told Benzinga back in April.

The Analyst

Cantor Fitzgerald analysts Elemer Piros and Justin Kim reiterated an Overweight rating on the stock, and increased their 12-month price target from $205 to $235/ADS.


The Thesis

“With the approval, GW Pharmaceuticals was granted a rare pediatric disease priority review voucher,” the note said.

Epidiolex has become the first FDA-approved drug containing a purified drug substance derived from cannabis.

“While Epidiolex is derived from cannabidiol (CBD), the FDA noted it does not cause intoxication or euphoria that is seen in tetrahydrocannabinol (THC). Additionally, Epidiolex is the first FDA approval for the treatment of patients with Dravet syndrome, and the first in a new category of anti-epileptic drugs (AEDs),” the analysts said.

Piros and Kim highlighted the encouraging fact that Epidiolex hadn't received a formal Boxed Warning, and a few upcoming catalysts for the company, including the DEA’s rescheduling meeting within the next 90 days, “an Epidiolex launch in fall 2018, and EMA decision by 1Q19. Additionally, the company will initiate a cannabidivarin (CBDV) investigator-led placebo controlled trial in autism in 3Q18 and a CBDV open label trial in Rett syndrome in 4Q18.”

Price Action

GW Pharma shares traded down about 4 percent to $145.05 at time of publication.

Related Links:

Canada Legalizes Recreational Marijuana Nationwide Beginning Oct. 17: Experts React

How Perpetually Sober KISS Co-Founder Gene Simmons Entered The Cannabis Business

Photo by Javier Hasse.

Posted In: Cannabiscannabis newscannabis oilcannabis stocksCantor FitzgeraldCBDCBD Epilepsymarijuanamarijuana newsmedicinal marijuanaTHCAnalyst ColorLong IdeasNewsPrice TargetReiterationFDATop StoriesAnalyst RatingsTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.